GSK: Japan approves new HIV two-drug pill

(CercleFinance.com) - GlaxoSmithKline has won approval to sell its once-daily, single-pill, two-drug regimen treatment of HIV in Japan, the world's second-biggest pharmaceutical market, the drugmaker said on Wednesday.


GSK's ViiV Healthcare has obtained approval of Dovato from the Japan Ministry of Health, Labour and Welfare for the treatment of HIV-1 infection, to be administered orally, it said.

The standard of care in Japan for people living with HIV has been with a three-drug regimen for many years.

Copyright (c) 2020 CercleFinance.com. All rights reserved.